Lymphocyte-Endothelial Cell Cross-Talk and Angiogenesis Depends on IL-12 Inhibition of Endothelial Cell Functions
暂无分享,去创建一个
M. Colombo | G. Forni | F. Bussolino | F. Cavallo | S. Mitola | M. Strasly | M. Geuna
[1] E. Hudson,et al. Differential expression and responsiveness of chemokine receptors (CXCR1–3) by human microvascular endothelial cells and umbilical vein endothelial cells , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] H. Hamada,et al. The Antiangiogenesis Effect of Interleukin 12 During Early Growth of Human Pancreatic Cancer in SCID Mice , 2000, Pancreas.
[3] S. Egawa,et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. , 2000, Cancer research.
[4] Hiroshi Yamamoto,et al. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells , 2000, Cancer Gene Therapy.
[5] P. Musiani,et al. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. , 2000, Cancer research.
[6] J. Elliott,et al. Activated lymphocytes promote endothelial cell detachment from matrix: a role for modulation of endothelial cell beta 1 integrin affinity. , 1999, Journal of immunology.
[7] G. Trinchieri,et al. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. , 1999, Cancer research.
[8] T. Olencki,et al. Interferon-γ and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma , 1999 .
[9] C Murdoch,et al. Cxc chemokine receptor expression on human endothelial cells. , 1999, Cytokine.
[10] A. Albini,et al. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[11] H. Okamura,et al. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. , 1999, Journal of immunology.
[12] R. Birge,et al. Integrin-mediated Activation of Focal Adhesion Kinase Is Required for Signaling to Jun NH2-terminal Kinase and Progression through the G1 Phase of the Cell Cycle , 1999, The Journal of cell biology.
[13] P. Musiani,et al. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. , 1999, Cancer research.
[14] S. Mahooti,et al. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. , 1998, Journal of cell science.
[15] D. Falcone,et al. Macrophage Formation of Angiostatin during Inflammation , 1998, The Journal of Biological Chemistry.
[16] C. Yeh,et al. Accutin, a New Disintegrin, Inhibits Angiogenesis In Vitro and In Vivo by Acting as Integrin vβ3 Antagonist and Inducing Apoptosis , 1998 .
[17] S. Weiss,et al. Matrix Metalloproteinases Regulate Neovascularization by Acting as Pericellular Fibrinolysins , 1998, Cell.
[18] R. Xavier,et al. Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.
[19] J. Teruya-Feldstein,et al. Contribution of the CXC chemokines IP‐10 and Mig to the antitumor effects of IL‐12 , 1998, Journal of leukocyte biology.
[20] Piero Musiani,et al. Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.
[21] J. Finke,et al. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. , 1998, Journal of immunology.
[22] S. Pestka,et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.
[23] M. Colombo,et al. Interferon γ–independent Rejection of Interleukin 12–transduced Carcinoma Cells Requires CD4+ T Cells and Granulocyte/Macrophage Colony–stimulating Factor , 1998, The Journal of Experimental Medicine.
[24] G. Trinchieri,et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. , 1998, The Journal of clinical investigation.
[25] E. Ohlstein,et al. Chemokine Receptors in Human Endothelial Cells , 1998, The Journal of Biological Chemistry.
[26] H. Luk,et al. Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v)beta3 integrin monoclonal antibody. , 1997, Biochimica et biophysica acta.
[27] S. Mandriota,et al. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. , 1997, Journal of cell science.
[28] P Signorelli,et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. , 1997, Journal of the National Cancer Institute.
[29] A. Mantovani,et al. Molecular mechanisms of blood vessel formation. , 1997, Trends in biochemical sciences.
[30] A. Mantovani,et al. Cytokine regulation of endothelial cell function: from molecular level to the bedside. , 1997, Immunology today.
[31] E. Holler,et al. Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: role of cytokines. , 1997, Blood.
[32] J. Farber. Mig and IP‐10: CXC chemokines that target lymphocytes , 1997, Journal of leukocyte biology.
[33] P. Brooks,et al. Role of integrins in angiogenesis. , 1996, European journal of cancer.
[34] G. Ciliberto,et al. IL-6 is an in vitro and in vivo autocrine growth factor for middle T antigen-transformed endothelial cells. , 1996, Journal of immunology.
[35] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[36] J. Becker,et al. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. , 1996, The Journal of clinical investigation.
[37] A. Angiolillo,et al. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.
[38] C. Garlanda,et al. Anti‐tumor activity of cytokines against opportunistic vascular tumors in mice , 1996, International journal of cancer.
[39] P. Dionigi,et al. Cell proliferation and ploidy of human solid tumours: methodological experience with in vivo bromodeoxyuridine and DNA flow cytometry. , 1996, Analytical Cellular Pathology.
[40] M. Colombo,et al. Hypoxic tumor cell death and modulation of endothelial adhesion molecules in the regression of granulocyte colony-stimulating factor-transduced tumors. , 1996, The American journal of pathology.
[41] J. Finke,et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. , 1996, Journal of immunology.
[42] Armen B. Shanafelt,et al. The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis (*) , 1995, The Journal of Biological Chemistry.
[43] F. Sarkar,et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.
[44] S. Soker,et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. , 1995, Cancer research.
[45] T. Eberlein,et al. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[46] P. Leder,et al. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation , 1995, The Journal of experimental medicine.
[47] R. D'Amato,et al. Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.
[48] D. Greiner,et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. , 1995, Journal of immunology.
[49] A. Mantovani,et al. Middle T antigen-transformed endothelial cells exhibit an increased activity of nitric oxide synthase , 1995, The Journal of experimental medicine.
[50] D. Cheresh,et al. Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.
[51] X. M. Sun,et al. The involvement of apoptosis in etoposide-induced thymic atrophy. , 1994, Toxicology and Applied Pharmacology.
[52] K. Kühn,et al. The structural bases of integrin-ligand interactions. , 1994, Trends in cell biology.
[53] T. Springer. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.
[54] L. Luistro,et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.
[55] M. Colombo,et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma , 1993, The Journal of experimental medicine.
[56] L. Naldini,et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth , 1992, The Journal of cell biology.
[57] A. Sica,et al. Murine endothelioma cell lines transformed by polyoma middle T oncogene as target for and producers of cytokines. , 1991, Journal of immunology.
[58] G. Forni,et al. In vitro reeducated T helper cells from sarcoma-bearing mice inhibit sarcoma growth in vivo. , 1984, Journal of immunology.
[59] L Orci,et al. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices , 1983, The Journal of cell biology.
[60] A. Whitmore,et al. Rous sarcoma virus-induced tumors in mice--I. Macrophage-mediated natural cytotoxicity. , 1982, European journal of cancer & clinical oncology.
[61] P. Libby,et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. , 1999, The American journal of pathology.
[62] T. Olencki,et al. Interferon-g and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma , 1999 .
[63] J. Teruya-Feldstein,et al. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. , 1999, Blood.
[64] B. Zetter,et al. Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.
[65] N. Copeland,et al. The CC chemokine 6 Ckine binds the CXC chemokine receptor CXCR 3 , 1998 .
[66] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[67] D. Cheresh,et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. , 1994, Cell.
[68] A. Mantovani,et al. The origin and function of tumor-associated macrophages. , 1992, Immunology today.
[69] B. Kindred. Nude mice in immunology. , 1979, Progress in allergy.